Selenium supplementation for polycystic ovary syndrome: a meta-analysis of randomized controlled trials

References

• McGowan MP. Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease. Curr Treat Options Cardiovasc Med. 2011;13(4):289–301.
   PubMedGoogle Scholar
• Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321–336.
   PubMed Web of Science ®Google Scholar
• Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: what’s new? Adv Clin Exp Med. 2017;26(2):359–367.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284.
   PubMed Web of Science ®Google Scholar
• Sadeghi HM, Adeli I, Calina D, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022;23(2):583.
   PubMed Web of Science ®Google Scholar
• Zhu T, Goodarzi MO. Causes and consequences of polycystic ovary syndrome: insights from Mendelian randomization. J Clin Endocrinol Metab. 2022;107(3):e899–e911.
   PubMed Web of Science ®Google Scholar
• Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545–1573.
   PubMed Web of Science ®Google Scholar
• Zeng X, Xie YJ, Liu YT, et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214–221.
   PubMed Web of Science ®Google Scholar
• Barrea L, Arnone A, Annunziata G, et al. Adherence to the mediterranean diet, dietary patterns and body composition in women with polycystic ovary syndrome (PCOS). Nutrients. 2019;11(10):2278.
   PubMed Web of Science ®Google Scholar
• Gargus ES, Bae Y, Chen J, et al. An ovarian steroid metabolomic pathway analysis in basal and polycystic ovary syndrome (PCOS)-like gonadotropin conditions reveals a hyperandrogenic phenotype measured by mass spectrometry. Biomedicines. 2022;10(7):1646.
   PubMed Web of Science ®Google Scholar
• Sangouni AA, Pakravanfar F, Ghadiri-Anari A, et al. The effect of l-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial. Eur J Nutr. 2022;61(3):1199–1207.
   PubMed Web of Science ®Google Scholar
• Bednarz K, Kowalczyk K, Cwynar M, et al. The role of glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int J Mol Sci. 2022;23(8):4334.
   PubMed Web of Science ®Google Scholar
• Rani R, Hajam YA, Kumar R, et al. A landscape analysis of the potential role of polyphenols for the treatment of polycystic ovarian syndrome (PCOS). Phytomed Plus. 2022;2(1):100161.
   Google Scholar
• Khorshidi M, Moini A, Alipoor E, et al. The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome. Phytother Res: PTR. 2018;32(11):2282–2289.
   PubMed Web of Science ®Google Scholar
• Di Tucci C, Di Feliciantonio M, Vena F, et al. Alpha lipoic acid in obstetrics and gynecology. Gynecol Endocrinol. 2018;34(9):729–733.
   PubMed Web of Science ®Google Scholar
• Lopes Junior E, Leite HP, Konstantyner T. Selenium and selenoproteins: from endothelial cytoprotection to clinical outcomes. Transl Res. 2019;208:85–104.
   PubMed Web of Science ®Google Scholar
• Spritzer PM, Lecke SB, Fabris VC, et al. Blood trace element concentrations in polycystic ovary syndrome: systematic review and meta-analysis. Biol Trace Elem Res. 2017;175(2):254–262.
   PubMed Web of Science ®Google Scholar
• Rashidi BH, Hosseinzadeh FM, Alipoor E, et al. Effects of selenium supplementation on asymmetric dimethylarginine and cardiometabolic risk factors in patients with polycystic ovary syndrome. Biol Trace Elem Res. 2020;196(2):430–437.
   PubMed Web of Science ®Google Scholar
• Razavi M, Jamilian M, Kashan ZF, et al. Selenium supplementation and the effects on reproductive outcomes, biomarkers of inflammation, and oxidative stress in women with polycystic ovary syndrome. Horm Metab Res. 2016;48(03):185–190.
   PubMed Web of Science ®Google Scholar
• Shabani A, Noshadian M, Jamilian M, et al. The effects of a novel combination of selenium and probiotic on weight loss, glycemic control and markers of cardio-metabolic risk in women with polycystic ovary syndrome. J Funct Foods. 2018;46:329–334.
   Web of Science ®Google Scholar
• Hosseinzadeh FM, Hosseinzadeh-Attar MJ, Yekaninejad MS, et al. Effects of selenium supplementation on glucose homeostasis and free androgen index in women with polycystic ovary syndrome: a randomized, double blinded, placebo controlled clinical trial. J Trace Elem Med Biol. 2016;34:56–61.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135(11):982–989.
   PubMed Web of Science ®Google Scholar
• Higgins JPT. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org.
   Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Zadeh Modarres S, Heidar Z, Foroozanfard F, et al. The effects of selenium supplementation on gene expression related to insulin and lipid in infertile polycystic ovary syndrome women candidate for in vitro fertilization: a randomized, double-blind, placebo-controlled trial. Biol Trace Elem Res. 2018;183(2):218–225.
   PubMed Web of Science ®Google Scholar
• Jamilian M, Razavi M, Fakhrie Kashan Z, et al. Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2015;82(6):885–891.
   PubMed Web of Science ®Google Scholar
• Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):P1–29.
   PubMed Web of Science ®Google Scholar
• Meier RK. Polycystic ovary syndrome. Nurs Clin North Am. 2018;53(3):407–420.
   PubMed Web of Science ®Google Scholar
• McCartney CR, Marshall JC. Polycystic ovary syndrome. N Engl J Med. 2016;375(1):54–64.
   PubMed Web of Science ®Google Scholar
• Juliawan IMP, Suwana FP, Annas JY, et al. High sucrose and cholic acid diet triggers PCOS-like phenotype and reduces enterobacteriaceae colonies in female wistar rats. Pathophysiology. 2022;29(3):344–353.
   PubMedGoogle Scholar
• Oztürk Z, Gurpinar T, Vural K, et al. Effects of selenium on endothelial dysfunction and metabolic profile in low dose streptozotocin induced diabetic rats fed a high fat diet. Biotech Histochem. 2015;90(7):506–515.
   PubMed Web of Science ®Google Scholar
• Sibal L, Agarwal SC, Home PD, et al. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6(2):82–90.
   PubMedGoogle Scholar
• Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discovery. 2011;10(4):277–291.
   PubMed Web of Science ®Google Scholar
• Luo Y, Yue W, Quan X, et al. Asymmetric dimethylarginine exacerbates Aβ-induced toxicity and oxidative stress in human cell and Caenorhabditis elegans models of alzheimer disease. Free Radic Biol Med. 2015;79:117–126.
   PubMed Web of Science ®Google Scholar
• Benstoem C, Goetzenich A, Kraemer S, et al. Selenium and its supplementation in cardiovascular disease–what do we know? Nutrients. 2015;7(5):3094–3118.
   PubMed Web of Science ®Google Scholar
• Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, et al. Selenium and coronary heart disease: a Meta-analysis. Am J Clin Nutr. 2006;84(4):762–773.
   PubMed Web of Science ®Google Scholar
• Orio F, Muscogiuri G, Nese C, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;207:214–219.
   PubMed Web of Science ®Google Scholar
• Jamilian M, Mansury S, Bahmani F, et al. The effects of probiotic and selenium co-supplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome. J Ovarian Res. 2018;11(1):80.
   PubMed Web of Science ®Google Scholar